Describing CBP-1008: a FR/ TRPV6 targeted drug conjugate in Phase II pivotal studies of advanced ovarian cancer treatment; Exploring CBP-1018: a FR/ PSMA targeted drug conjugate in Phase Ib for prostate cancer therapy; Highlighting CBP-1019: TOP1i payload drug conjugate for unmet medical needs
9 months ago
Clinical
|
TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6)
Multiple SD and PSA decrease were observed at DLs of 0.08-0.14 mg/kg, conferred a promising preliminary antitumor activity in pts with mCRPC despite of COVID-19's impacts. MTD was not reached and dose-escalation to establish the RP2D is continuing.